Cue Biopharma is trading 8.44% up at $17.44 in pre-market on October 20, 2026; no new company announcement explaining the move was identified.
- Positive CUE-221 Phase 2 results were announced September 20, with the trial meeting its primary and key secondary endpoints; the news is several weeks old.
- Biotech-sector weakness is reflected in XBI’s 3.65% decline, while major U.S. indices are mixed.
- Available evidence does not clearly link the gain to a current company-specific or market-wide catalyst.